toreforant   

GtoPdb Ligand ID: 9276

Synonyms: JNJ-38518168
Compound class: Synthetic organic
Comment: Toreforant is a selective histamine H4 receptor antagonist claimed as Example 7 in patent WO2007117399 [1]. It is being investigated for its potential antiinflammarory action in allergy, asthma, autoimmune diseases, and pruritis.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 69.73
Molecular weight 392.27
XLogP 3.64
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES CN1CCC(CC1)CCCNc1ncc(c(n1)C)c1nc2c([nH]1)cc(cc2C)C
Isomeric SMILES CN1CCC(CC1)CCCNc1ncc(c(n1)C)c1nc2c([nH]1)cc(cc2C)C
InChI InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)
InChI Key FCRFVPZAXGJLPW-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
Toreforant failed to show clinical efficacy in a Phase 2 clinical trial in patients with active rheumatoid arthritis [2]. Phase 2 studies NCT01823016 and NCT02295865 in patients with uncontrolled, persistent asthma and moderate to severe plaque-type psoriasis respectively have been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01823016 A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma Phase 2 Interventional Janssen Research & Development, LLC
NCT02295865 A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis Phase 2 Interventional Janssen Research & Development, LLC